Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29689791 | 0.81 | LMNA (0.40) | LMNABRD4ADORA2API4KAPI4K2B | |
| SCHEMBL23607656 | 0.81 | CYP1A2 (0.44) | LMNABRD4ADORA2AALDH1A1CYP1A2 | |
| SCHEMBL29382308 | 0.81 | CYP1A2 (0.44) | LMNABRD4ADORA2AALDH1A1CYP1A2 | |
| SCHEMBL23579642 | 0.81 | CYP17A1 (0.49) | LMNABRD4ADORA2API4KAPI4K2B | |
| SCHEMBL3922575 | 0.80 | LMNA (0.50) | LMNABRD4ADORA2ACYP11B1CYP11B2 | |
| SCHEMBL4296902 | 0.79 | MEN1 (0.59) | LMNAADORA2ACYP11B1CYP11B2TNF | |
| SCHEMBL24444297 | 0.77 | EGLN3 (0.46) | LMNABRD4CYP11B1CYP11B2TNF | |
| SCHEMBL23579933 | 0.77 | DPP4 (0.54) | CYP1A2KMT2A | |
| SCHEMBL23579969 | 0.74 | CYP11B1 (0.42) | LMNAADORA2ACYP11B1CYP11B2EGLN3 | |
| SCHEMBL3767345 | 0.74 | CYP11B1 (0.66) | LMNABRD4CYP11B1CYP11B2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339150-B2 | Benzimidazole compounds as HDAC6 inhibitors | ONKURE, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2021133957-A1 | BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS | ONKURE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| EP-2041118-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339150-B2 | Benzimidazole compounds as HDAC6 inhibitors | HDAC6, HDAC1, HDAC11 | LMNA 1225/4885BRD4 39/4885ADORA2A 4110/4885 |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | MAPT, IAPP, MYLK2 | LMNA 3794/4885BRD4 1496/4885ADORA2A 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.